A Balanced Risk–Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)—The Case of Tea and Herbal Infusions by Habs, Michael et al.
nutrients
Review
A Balanced Risk–Benefit Analysis to Determine
Human Risks Associated with Pyrrolizidine
Alkaloids (PA)—The Case of Tea and
Herbal Infusions
Michael Habs 1, Karin Binder 2, Stefan Krauss 2, Karolina Müller 3, Brigitte Ernst 4,
Luzia Valentini 5 and Michael Koller 3,*
1 Faculty of Medicine, LMU—University of Munich, 80333 Munich, Germany; info@michael-habs.de
2 Didactics of Mathematics, University of Regensburg, 93053 Regensburg, Germany;
Karin.Binder@mathematik.uni-regensburg.de (K.B.); stefan1.krauss@mathematik.uni-regensburg.de (S.K.)
3 Centre for Clinical Studies, University Hospital Regensburg, 93042 Regensburg, Germany;
Karolina.Mueller@ukr.de
4 General Medicine Unit, University Hospital Regensburg, 93053 Regensburg, Germany;
dr.b.ernst@t-online.de
5 Institute of Evidence-based Dietetics, University of Applied Sciences Neubrandenburg,
17033 Neubrandenburg, Germany; valentini@hs-nb.de
* Correspondence: michael.koller@ukr.de; Tel.: +49-941-944-5630; Fax: +49-941-944-4462
Received: 29 May 2017; Accepted: 3 July 2017; Published: 7 July 2017
Abstract: Humans are exposed to pyrrolizidine alkaloids (PA) through different sources, mainly from
contaminated foodstuff. Teas and herbal infusions (T&HI) can be contaminated by PA producing
weed. PA can possess toxic, mutagenic, genotoxic, and carcinogenic properties. Thus, possible
health risks for the general population are under debate. There is a strong safety record for T&HI
and additionally epidemiological evidence for the preventive effects of regular tea consumption on
cardiovascular events and certain types of cancer. There is no epidemiological evidence, however,
for human risks of regular low dose PA exposure. Recommended regulatory PA-threshold values
are based on experimental data only, accepting big uncertainties. If a general risk exists through PA
contaminated T&HI, it must be small compared to other frequently accepted risks of daily living
and the proven health effects of T&HI. Decision making should be based on a balanced riskbenefit
analysis. Based on analyses of the scientific data currently available, it is concluded that the benefits of
drinking T&HI clearly outweigh the negligible health risk of possible PA contamination. At the same
time, manufacturers must continue their efforts to secure good product quality and to be transparent
on their measures of quality control and risk communication.
Keywords: pyrrolizidine alkaloids (PA); risk–benefit analysis; tea and herbal infusions
1. Introduction
Pyrrolizidine Alkaloids (PA) are synthesized by many plants and occur ubiquitously in the human
environment. More than 660 PA in 6000 plants have been described [1–3]. They can contaminate
biological products, including foodstuff, herbal remedies, supplements, and beverages [4,5].
The toxicity of PA only occurs after metabolic activation. Different competing metabolic pathways
can lead to detoxification or poisoning. PA tested for toxicity differ broadly in experimental toxic
potency [3,6]. Toxicity depends on chemical structure, is species-specific, modulated by gender, age, and
the current metabolic situation [1]. Experimental toxicology shows PA to possess acute and chronic
toxicity. The primary site for metabolic activation and the main target organ is the liver [7]. Hepatic
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occlusive disease, also called hepatic sinusoidal obstruction syndrome, is the typical result of acute PA
poisoning, well documented experimentally and in livestock poisoning [8].
Some human anecdotal cases of PA associated liver damage have been described in the literature,
of which only a few cases are well documented [2,6,9–11]. The lung can be affected by PA if
pyrrolic metabolites escape from the liver and damage pulmonary arterioles [8]. Single case reports
show transplacental exposure to lead to acute liver failure of the fetus without signs of maternal
toxicity [12–14]. In developed countries one would expect primarily chronic damages resulting from
long-term, low-dose exposure [2,6,9].
If teas (derived from Camellia sinensis, usually containing caffeine) and herbal infusions (derived
from herbs and/or fruits, usually caffeine-free) (T&HI) are frequently contaminated, they always can
become a major source for human exposure with the involved contaminants due to the worldwide
extensive habit of drinking T&HI [15]. Correspondingly, T&HI are a prominent case to analyze the
possible impact of PA contaminations in food. To assess the human safety of drinking T&HI, which can
be contaminated with PA, numerous facts need to be considered. The traditional purpose of effective
risk assessment and risk control is to prevent morbidity and mortality in humans.
However, regarding drinking T&HI, a balanced risk–benefit analysis is necessary that includes
both, the potential risks of PA contaminations and the beneficial effects of drinking tea in general.
The available evidence suggests that drinking T&HI is a beneficial custom resulting in improved health
conditions [16–18].
The present paper provides a comprehensive overview of the current state of knowledge on PA
and PA research, including evidence from experimental and human trials for health effects as well as
toxicity, pathogenesis, and etiology of toxic effects as well as limitations of modern analytical detection
methods. Finally, we try to put PA-related risks in perspective with more general health and everyday
life risks. Taken together, this should enable stakeholders and consumers to engage in evidence-based,
rational risk communication and informed decision making.
2. Health Effects and Safety of Consuming Tea and Herbal Infusions
Many beneficial health effects of drinking teas have been reported [16,17,19,20]. Recently tea in
health and disease prevention has been reviewed [21]. In the last decade, more than 3000 studies,
including fifty epidemiologic studies of the association between tea drinking and cancer risk reduction,
have been published. A correlation between tea consumption and reduced cancer risk has been
described for colon cancer, breast cancer, cancer of the ovary, and prostate cancer [22].
Epidemiological data from cohort studies and cross-sectional studies suggest a strong association
between drinking green tea and a reduced incidence of liver diseases including hepatocellular
carcinoma and liver cirrhosis [23,24]. A meta-analysis of observational studies on the association
between tea drinking and a risk reduction for depression produced a dose response relationship:
A linear association between tea consumption and risk decrease was shown with an increment of three
cups/day leading to a risk decrease of 37% [25].
Moreover, tea consumption has been associated with a reduced risk to develop type 2 diabetes
showing a linear inverse connection between tea drinking and type 2 diabetes [26]. With every
additional two cups/day the risk to develop diabetes is reduced by 4.6% [27].
In addition, for cardiovascular diseases observational studies present an association between
increasing tea consumption and risk reduction. A recent meta-analysis reported an increase in tea
drinking by three cups/day being associated with a significantly reduced relative risk for coronary
heart disease of 0.73, for cardiac death of 0.74, for stroke of 0.82, for cerebral infarction of 0.84, and for
cerebral hemorrhage of 0.79 [28].
A Canadian qualitative study reported results from interviews with women who participated in
the occupations of a Japanese tea ceremony [29]. Engaging in the tea ceremony enabled the sharing of
common emotions, a sense of ongoing personal development, concentration, and a feeling of presence.
The investigation shows that the culture of preparing and drinking tea can help to de-stress and to
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support living life mindfully, and to facilitate psychological well-being and mental balance beyond
pharmacological effects [29]. The conscious habit of drinking tea is often rated as a desirable social
behavior with positive connotations embedded in a traditional cultural context.
The polyphenols of Camellia sinensis with epigallocatechin-3-gallate as a lead constituent possess
potent antioxidant capacity linked to the prevention of oxidative stress, modulation of toxicokinetic
carcinogens and prevention of DNA adduct formation as possible modes of action [26]. There is also
additional evidence that black tea drinking can improve recovery from psychophysiological stress [30].
In contrast to tea, popular herbal infusions (HI, herbal teas, and tisanes) used for medical purposes
are made from, among others, chamomile, cinnamon, fennel, ginger, lemon balm, nettle, peppermint,
rosemary, and valerian [10,11]. HI used as herbal medicinal products have medical indications
either based on traditional use (Table 1) or supported by clinical studies leading to well-established
indications. As medical products, they have a positive ris-benefit ratio as a prerequisite for market
access. The herbals given in Table 1 are also used in common HI. No harmonized frame exists among
the European countries what is regarded as food versus medical product. The Tea & Herbal Infusions
Europe list of herbals considered as food is a compendium of the different herbal materials consumed
as food ingredients in herbal teas and fruit teas in Europe [31]. It names several hundreds of plants and
part of plants currently used by the herbal infusions trade. National use of HI is driven by tradition and
behavioral trends. In 2013, the consumption of HI (including fruit teas) in Germany by far exceeded
the use of tea (per capita consumption 40 L vs. 28 L). Leading single herb teas were peppermint leaf,
fennel fruit, and chamomile flower [32].
In summary, there is consistent and increasing evidence based on experimental, clinical, and
epidemiologic data that drinking T&HI is a healthy habit resulting in improved health conditions.
Table 1. Herbal teas.
Herb Indications Evidence Monograph
Chamomilla
(Matricaria chamomilla)
digestive ailment, bloating, flatulence,
restlessness, mild insomnia anecdotal, traditional use [33]
Cinnamon
(Cinnamomum verum) digestive ailment, mild diarrhea anecdotal, traditional use [34]
Fennel
(Foeniculum vulgare) dyspepsia, spasmodic ailments traditional use [11,35]
Ginger
(Zingiber officinale)
dyspepsia, flatulence, prevention of
nausea, vomiting, motion sickness
well established and
traditional use [36]
Lemon balm
(Melissa officinalis)
mild symptoms of stress, anxiety
and insomnia traditional use [37]
Nettle (Urtica dioica) lower urinary tract symptoms relatedto benign prostatic hyperplasia traditional use [36]
Peppermint
(Mentha piperita)
digestive disorders, nausea,
abdominal pain traditional use [11]
Rosemary
(Rosmarinus officinalis)
dyspepsia, mild gastrointestinal
spasmodic disorders traditional use [38]
Valerian
(Valeriana officinalis)
mild nervous tension and
sleep disorders traditional use [39]
Safety Assessment of Drinking Tea
Caffeine is the best documented bioactive ingredient in tea. When individuals consume moderate
amounts, positive effects on human behavior become apparent through increased alertness and
vigilance and reduced fatigue [40]. Reports on negative effects (increased anxiety, sleep disorders,
and fine motor control affection) are linked to very large amounts given to sensitive groups
(e.g., patients with anxiety disorders) [32]. The evidence clearly shows that levels consumed by
most people have largely positive effects on behavior [40]. In a recent scientific opinion, the European
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Food Safety Authority (EFSA) Nutrition and Allergies (NDA) Panel concluded caffeine intakes from all
sources up to 400 mg consumed throughout a day do not give rise to safety concerns for healthy adults
in the general population [40]. In Europe, the mean daily caffeine consumption from tea and coffee
is below this safety value in all 17 analyzed countries [40], however, in seven of these countries the
95% percentile estimate is above 400 mg [41], suggesting that at least 5% of the population consumes
amounts above the safety threshold.
Three Cochrane Reviews dealing with green or black tea preparations have been published [19,20,42].
They studied green tea interventions for weight control, green and black tea for primary prevention
of cardiovascular disease, and green tea for cancer prevention. Tea preparations with different
standardization of active ingredients were pooled, and studies were performed in various patient
groups and cultural settings. The controlled situation of interventional studies has the convincing
advantage that possible unwanted effects will be far better identified than in daily use. That is why the
results on safety from these three intervention reviews are of major importance. In the weight loss and
weight maintenance review [42] is summarized that most adverse effects, such as nausea, constipation,
abdominal discomfort, and increased blood pressure are mild to moderate and partly unrelated to
green tea intervention. In the prevention studies of cardiovascular disease [19], the only adverse events
measured were unlikely to be related to the intervention. From the cancer prevention trials the authors
conclude that drinking green tea appears to be safe at moderate, regular, and habitual use [20].
Neither Camellia sinensis nor one of the common herbals used for making infusions was shown to
produce PA. If PA occur in teas, it is the result of contamination with weeds.
We conclude that the habit of regularly drinking T&HI in usual amounts is safe. Therefore,
we focus on the possible risk of PA contamination.
3. PA Toxicity: Analytical Detection, Pathogenesis, and Etiology
3.1. Analytical Detection of PA
Today, mass spectrometry (MS) can analyze PA at trace levels. In principle, two MS based
approaches are applied, either in combination with gas chromatography (GC) or high performance
liquid chromatography (HPLC) in tandem mass-spectrometry (MS/MS) mode [43,44].
A limited but increasing number of validated reference standards for PA are commercially
available. The German Institute for Risk Assessment (BfR) recently listed 35 PA reference standards [2,9].
Due to structural diversity, low concentrations, and ubiquitously existence, PA analysis in the
environment and in processed products poses substantial challenges. Validation of specific detection
methods and strategies for screening processes are in progress. A current inter-laboratory comparison
study for PA in animal feed using spiked and incurred material showed 3 out of 12 laboratories
scored consequently positive or negative results. Two laboratories reported false positive results
with a blank sample. Inter-laboratory variations led to the conclusion that the methods used for
PA detection need further development for accurate estimation of contaminated feed [45]. Another
inter-laboratory comparison organized by BfR with 31 participants investigated three PA contaminated
herbal tea samples, one rooibos tea sample and a dissolved PA mixture. The observed discrepancies
between the results of the participating laboratories showed room for methodical improvement and
better standardization of operating procedures and performance criteria [46]. For comparability of
analytical results, EMA Committee on Herbal Medicinal Products (HMPC) has requested that the
European Pharmacopoeia considers development of an appropriate analytical method for PA a matter
of priority [47]. EFSA and BfR recommend for sampling to use the Commission Regulation (EC) No
401/2006 laid down for mycotoxins as guidance for the control of the levels of PA in foodstuff [48].
Some health authorities have set a limit of 1.0 µg PA per day for the final product during
a transitional phase. As a base for preventive measures the focus should be on the effects of combined
human exposure of different PA from different sources, but no health-based guidance value has been
established for the daily sum of PA from different sources. There are no binding test methods currently
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available. Recommendations from regulatory authorities prefer to measure the sum of quantified PA
obtained by using validated reference substances of individual PA [2,5,9].
In summary, the threshold values discussed so far have the status of guidance, but not of legally
binding limits. The same is true for analytical detection methods, which have not been harmonized
yet [2,3,9].
3.2. PA Induced Toxicity: Pathogenesis
The chemical structure defines the toxicity of PA. Only 1,2-dehydropyrrolizidine-alkaloids are
relevant for toxic effects [49]. PA without this structural feature are considered non-toxic. The native
parent PA are nontoxic. Toxicity requires metabolic activation of highly reactive compounds.
Animal studies have shown that reactive metabolites are formed after metabolic activation via
CYP 3A4 enzymes [42]. These alkylating reactive metabolites bind to macromolecules, including DNA.
Toxicodynamic investigations in mammals show quick absorption across the gastrointestinal tract,
transport to the liver as the primary site for metabolic activation, renal excretion, and transplacental
transport as well as transmission of water-soluble metabolites into the lung and skim breast milk [7].
Ingested PA are rapidly metabolized in the liver and the excretion of unchanged alkaloid and of
most metabolites is rapid as well [6]. The European Medicines Agency concluded from the available
toxicokinetic experimental data that within a few hours, only a relatively small proportion of the
applied dose remains in the body, much of it in the form of metabolites bound to tissue constituents [4].
It is unlikely that a significant amount of unchanged alkaloid will remain in the body after the first
day [4].
Metabolism steps involving cytochromes P-450 and flavin-containing monooxygenases can either
lead to activation (toxification) or to detoxification [4].
The activation pathway is oxidation of the PA to form the dehydropyrrolizidine derivative (also
referred to as the dehydronecine). Further biotransformation involves enzymatic or non-enzymatic
glutathione conjugation or hydrolyses at the ester bond to form the dehydropyrrolizidine.
Detoxification occurs by esterase cleavage leading to release of the necine base and necic acid(s).
N-oxidation is generally catalyzed by a variety of mixed function oxidases, involving cytochromes
P-450 and flavin-containing monooxygenases. N-oxides are highly water soluble and rapidly excreted
via urine [1,4,6].
The pathogenesis of hepatotoxicity following PA exposure is only partially defined. Already
for the hepatocyte, six different mechanisms of liver injury are known [49]. In PA liver toxicity, not
only the hepatocytes are involved but also sinusoidal endothelial cells and central vein endothelial
cells. Hepatocytes and sinusoidal endothelial cells metabolize the PA monocrotaline to toxic
intermediates, but sinusoidal cells seem more sensitive to toxicity than hepatocytes. It has been
discussed that the susceptibility of this cell type is due to a lower glutathione content leading to a greater
intracellular exposure to toxic metabolite(s) due to a lower capacity for detoxification. This viewpoint
is strengthened by the finding that in the monocrotaline model a concomitant infusion of glutathione
dose dependently protected rats from development of hepatic veno-occlusive disease [50,51]. It is
obvious that hepatic toxicity of monocrotaline is triggered by an overload of the detoxification systems
of the liver. This finding suggests a threshold dose for this type of toxicity.
The toxicities of individual PA in biological systems are not only based on PA structural
features but also on the pattern of expression and the selectivity of the CYP isoforms present [52].
Inter-individual enzyme concentrations of liver CYP3A4 and CYP3A5 vary over a 30-fold range [1,8].
Obviously individual susceptibility varies greatly within species and between species, gender, and
individuals and over time, triggered by disposition and external factors, e.g., exposure to enzyme
inducers. It remains unclear whether these differences are qualitative and/or quantitative in nature [53].
Gene expression profiling of liver genes of rats fed comfrey or dosed with the PA senecionine and
riddelliine are an initial approach for revealing biological pathways and networks associated with
toxicity and carcinogenicity induced by PA [54]. Genome transcriptome analysis in primary human
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hepatocytes exposed to four different PA, i.e., echimidine, heliotrine, senecione, and senkirkine showed
all four PA to regulate a great number of genes in common, proposing similar molecular mechanisms,
although the extent seems to differ [55].
Most primary liver tumors arise based on chronic liver inflammation subsequently inducing
fibrogenesis and, ultimately, liver cirrhosis. The constant inflammatory cell death also promotes
the development of phenotypic and molecular heterogeneity characteristic for hepatocellular
carcinomas [56]. The presumption of similarity of rodents to humans may be test compound-specific [57]
and the relevant mode of action for PA carcinogenesis in high doses in rodents may be different from
the mode of action of low doses in humans.
3.3. PA Induced Toxicity: Etiology
No long-term animal studies have investigated the effects of food or beverages contaminated
with PA. From long-term studies in rodents with different Ginkgo extracts it is known that
toxic effects, including carcinogenicity, depend on the specific composition of the investigated
extracts. Single components of an herbal extract may show carcinogenic properties, but the complex
extract does not [58]. To extrapolate from high-dose animal studies with single, chemically defined
PA to manufactured products occasionally contaminated with varying (comparatively low dose)
concentrations is highly speculative. It is not known which concentration of individual PA or PA
combinations or PA containing extracts or infusions result in which metabolism pattern leading to
detoxification, acute, sub-acute, or chronic toxicity [3,4,7]. Rules for changes of enzyme patterns
induced by repeated dosing or by combination with other xenobiotica have not been established [59].
In experimental animals, livestock poisoning by hay and plants containing PA and in human
case reports (including transplacentally exposed infants) of accidental poisoning with PA containing
herbal mixtures in high doses lead to acute liver toxicity with veno-occlusive disease, a specific form
of damage to the microcirculation of the liver, also called hepatic sinusoidal obstruction syndrome.
Cases of illness have been described in the literature, but there are only a few well documented
cases [2,9]. In the general population one would expect primarily chronic damage, i.e., carcinogenic,
mutagenic, and teratogenic effects and human hepatic veno-occlusive disease [6]. Human single case
reports show that transplacental exposure can lead to acute liver failure of the fetus without signs of
maternal toxicity [14].
Exposure to a single oral dose of 160 mg/kg body weight of monocrotaline is used as
a reproducible animal model for this type of hepatotoxicity [60]. However, the dose used corresponds
in a human equivalent dose of 1.5 g for an adult [61], which by orders of magnitude exceeds human
exposure [41,62].
Human hepatic veno-occlusive disease is the most prominent hepatic lesion associated with PA
poisoning, but in general it is a very rare event. Liver diseases associated with PA-contaminated
grain, have been reported for Pakistan, India, and Afghanistan [63]. Diagnosis is usually based
on symptoms and on patients’ reports of having ingested substances associated with pyrrolizidine
alkaloids. The latest outbreak in Afghanistan occurred in 2008. Sixty-seven cases of human hepatic
veno-occlusive disease were identified in a case-control survey. A total of 28,443 individuals were
surveyed, and 199 controls were matched with cases [63]. Consumption of bread was strongly
associated with these cases. Thirty-two samples of flour were collected and analyzed for PA by
means of liquid chromatography/mass-spectrometry. Median total concentration of PA in 12 samples
taken from houses with liver disease cases was 5.6 mg/kg compared to 2.7 mg/kg in 20 control
samples. The authors observed that identified cases were significantly more likely to report frequent
consumption of bread [63]. Correspondingly, flour samples taken from case houses were found to
be contaminated with high levels of PA stemming from contamination with seeds of Heliotrope or
Crotalaria varieties [63]. In modern agricultural professional practice, this type of grain contamination
is unlikely to occur because contamination with PA synthesizing plants in this type of farming is
negligible [12].
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The toxic effects of PA consumed in large doses over a short period manifest in humans as
veno-occlusive disease, the occlusion of central venules is pathognomonic. BfR reported a case of an
adult who had eaten plant material containing PA which caused severe liver function disease [2,9].
Rasenack and coworkers informed on the occurrence of human hepatic veno-occlusive disease in a
preterm neonate who was delivered by caesarean section and died shortly afterwards [60]. Post-mortem
examination confirmed the diagnosis and content of PA in the liver of the fetus. Analysis of an herbal
mixture which was used for cooking in the family demonstrated high amounts of PA, establishing the
casual relationship [14].
No general safety limits for acute toxicity in humans have been established from epidemiological
or clinical data.
4. PA Toxicity: How Do Experimental Models and Findings in Humans Fit Together?
4.1. Combination of Animal and Human Toxicity Data Demonstrate the Relevance of Analogous Manifestation
of Toxicity
The carcinogenicity of PA contaminated food has never been investigated in long-term animal
studies. Chronic animal toxicity of single PA or extracts containing PA results in hepatic vein
occlusions, mutagenic, teratogenic, and carcinogenic effects [6]. In rodents, the signal tumor of
chronic PA poisoning is hepatic hemangiosarcoma [64,65]. It is concluded that inter-species qualitative
comparability of metabolism and toxicity is feasible but huge quantitative differences are obvious. It is
an open question whether the differences in metabolic cell response between rodents and humans
should disqualify animal data for quantitative risk assessment in humans [53].
Risk assessment extrapolating animal findings to humans quantitatively implies major
uncertainties. The reliability of animal data to predict outcome in humans has been critically reviewed
by different working groups [66,67]. In general, comparisons between animal and human data show
that findings in animals were not reliably replicated in humans. Heywood reported that animal
experiments poorly predict adverse effects of pharmaceuticals and concluded “the best guess for
the correlation of adverse reactions in man and animal toxicity data is somewhere between 5 and
25%” [66]. Olson et al. [67] analyzed the concordance of the toxicity of pharmaceuticals in humans
and animals in a multinational pharmaceutical company survey compiling data from 12 companies
with 150 compounds in clinical development. Non-rodent experiments predicted 63% of human organ
toxicity, studies in rodents 43%, respectively. These discrepancies are thought to be due to differences
in physiology and metabolism.
The value of animal use in the field of regulatory toxicology relies on a codified set of highly
standardized acute, repeated dosing, and long-term animal studies, many of them developed in the
1960s. Their relevance has been scrutinized as more modern concepts became available to predict
human outcome after exposure to xenobiotics [68–70]. However, if rare tumor types found in humans
correspond to tumors in animal tested with the same suspected carcinogenic agent this is a reasonable
empirical argument for causality. Identical organotropism and comparable tumor pathology have been
demonstrated for about 50% of the chemicals, which are accepted by the World Health Organization
(WHO) as carcinogenic to humans [71].
Hemangiosarcoma of unknown origin (“spontaneous tumors”) occur frequently in mice, are
unusual in rats [46], and are well known in cats and special breeds of dogs [72]. Comparative gene
expression profiling studies in Golden Retrievers suggest genetic background to mold occurrence,
phenotype and biological behavior of sporadic hemangiosarcomas, at least in dogs [73]. These findings
reveal that the risk of developing hemangiosarcoma could depend upon genetic disposition.
Carcinogens associated with liver carcinomas and hemangiosarcomas of the liver in humans
include Alpha-emitters, vinyl chloride, and arsenic. Intravenous injection of thorium dioxide induced
hepatocellular carcinomas in hamsters and liver carcinomas, intrahepatic bile-duct carcinomas,
and hemangiosarcomas in rats [71]. Hepatic angiosarcomas can be reproducibly induced in rodents by
exposure to vinyl chloride in the air [74].
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Rodent liver angiosarcomas develop following exposure to DNA reactive, genotoxic chemicals as
well as following chronic exposure to non-DNA reactive, non-genotoxic xenobiotics. Cohen et al. [53]
have composed different modes of action for different mechanisms leading to hepatic angiosarcoma
in rodents. Dysregulated angiogenesis can lead to local hypoxia followed by an overexpression of
hypoxia-inducible factor 1-alpha (HIF) and vascular endothelial growth factor (VEGF), macrophage
activation and thus locally increased interleukin-6 (IL-6) concentration. Both, VEGF and IL-6,
can stimulate endothelial cell proliferation. The European Medicines Agency (EMA) statement [4]
describes stimulation of cell proliferation following local hypoxia as a mode of action for hepatic
angiosarcoma in rodents following exposure to PA. There are several mechanisms by which
carcinogens cause cancer [75,76]. The mechanisms include DNA-methylation, histone methylation
and acetylation, micro-RNA expression, receptor binding (aryl hydrocarbon, nuclear, peroxisome
proliferator, and hormonal receptors), cytotoxicity, hormonal imbalance, chronic inflammation,
oxidative stress, inhibition of apoptosis, disturbances in cell to cell communication, and induction
of cell proliferation [76]. Dose thresholds have been shown experimentally for tumor induction by
non-genotoxic tumor development. There is no proof that genotoxic compounds lead to carcinogenicity
only through gene mutations. The hypothesis for genotoxic compounds assumes that one DNA
mutation is sufficient to initiate a cancer cell. This hypothesis has not yet incorporated the better
understanding of molecular mechanisms of DNA repair and apoptosis [77]. There appear to be
significant tissue-specific and species-specific differences between the responses of endothelial cells to
xenobiotics. It remains unclear whether these differences are qualitative and/or quantitative in nature.
To ultimately address the question of interspecies comparisons a better understanding of biological
similarities and differences between rodents and humans is needed.
Corresponding findings in (experimental) animals and humans strengthen the plausibility of
a causative relationship and thereby move up the importance of the experimental findings in the
hierarchy of evidence [62]. As shown in the paragraph on the etiology of PA induced toxicity
experimental data, livestock poisoning and accidental human intoxications are comparable in acute
and subacute toxicity. After PA poisoning many patients recover almost completely if the alkaloid
intake is discontinued; cases of liver fibrosis and cirrhosis have been reported but no case of human
liver malignancies has been linked to PA ingestion [13,62].
In regulatory toxicology, we assume threshold doses for most toxic effects. PA have the potential to
produce several forms of toxicity. Acute intoxications are a result of overload of metabolic detoxification
pathways and can result in secondary consequences such as hepatic occlusive disease. These effects
assume a dose threshold below which no signs of toxicity occur. Due to metabolic detoxification of low
doses no manifestation of acute and subacute liver toxicity is expected in the general population of
developed countries with high agricultural standards [2,6]. This still leaves the question unanswered:
what is the risk of possible low-dose, long-term exposure to PA by food contaminants?
Different approaches have been suggested to translate animal doses to human exposure risks.
These calculations try to bridge speciesspecific differences, e.g., in genetic diversity, life expectancy,
and basic metabolic pathways [78]. FDA has published a guidance document describing the use of
standard specific factors that allow conversion of animal doses in (mg/kg) to human doses in (mg/kg)
using the body surface area as the common denominator [79].
European regulators favor the margin of exposure approach to translate doses used in animal
experiments to human exposure. Safety factors (in general of 10,000) are introduced to compensate for
the knowledge gap in translating the benchmark dose lower confidence limit 10% (i.e., 95% confidence
limit of the lowest dose showing a specific toxic effect in 10% of the exposed animals) in animals to the
human situation [43].
EFSA has used the margin of exposure approach to translate the benchmark lower dose
confidence limit for a 10% excess cancer risk of 70 µg/kg body weight per day for induction of liver
hemangiosarcomas by lasiocarpine in male rats to a reference point for comparison with estimated
dietary human exposure [43]. The quality of estimates in translating experimental findings to the
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human situation very much determines how efficiently the toxicity of PA in humans is controlled
and prevented.
Since in carcinogenesis experiments PA induce hepatocellular carcinomas and hemangiosarcomas
of the liver in the rat, it is worthwhile to look for a match with analogous malignancies in humans.
4.2. Epidemiological Evidence
In 2012, 782,000 new cases of liver cancer were diagnosed worldwide [80]. In the United
States, 39,230 new cases of primary liver cancer (hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (HCV)) are estimated for 2016 [81]. Other sources report about 21,000 men and
8000 women to newly develop primary liver cancer annually, while 27,170 people (18,280 men and
8890 women) are estimated to die of primary liver cancer in 2016 [81,82]. Thus, for calculation purposes,
25,000 deaths/year and twice as many men affected than women seem reasonable figures.
The overall rates of HCC tripled between 1975 and 2005. This increase is explained by the rise in
hepatitis B and C virus carriers [83]. Major risk factors for HCC are chronic infection with hepatitis C
and hepatitis B virus, excessive alcohol consumption, obesity, diabetes, metabolic syndrome, all can
lead to liver cirrhosis. Smoking and eating foods with aflatoxin burden have also been associated
with HCC [84–86]. HCV has been associated with several diseases of the biliary tract or liver, such as
primary sclerosing cholangitis, Caroli disease, cholelithiasis, cholangitis, liver fluke, and inflammatory
bowel disease.
No epidemiological data exist to associate chronic low dose PA exposure with human disorders [2,9,62].
The total number of primary liver cancer minus known attributable risks leaves only a low to very low
risk for unknown causes. Theoretically, a fraction thereof could be associated with PA intake. The risk
estimate attributable to hepatic infections accounts for well over 80% of all primary liver cancers. Thus,
less than 20% are left for all other well established factors and for cancer of yet unexplained etiology,
including a theoretical minority portion associated to chronic PA exposure) [82,87–90].
By subtracting the cases attributable to hepatitis (25,000 − >20,000 = <5000), a theoretical number
of <5000 new cases/year can be calculated for the US population. Within these <5000 cases must be
those due to known risk factors besides hepatitis B and C. The possible impact of PA contamination
stays speculative, but is negligible compared to the impact of the sum of tumors probably attributable
to already well-recognized risks. Thus far, no clinical association has been described between human
cancer and exposure to PA. Based on the extensive reports on the outcome of human exposure available
in the literature, Prakash, Pereira, Reilly, and Seawright [91] concluded that, while humans face the
risk of veno-occlusive disease and childhood cirrhosis by PA poisoning, PAs are not carcinogenic to
humans. 2500 annual cases linked to PA uptake seem clearly above a reasonable educated guess.
Human hepatic hemangiosarcoma (HHA) is a rare tumor [92,93], one source states HHA to
account for only 2% of primary liver malignancies. Other authors estimated that only about 10 to 25
such cases occur each year in the United States [94,95]. Zochetti reported its frequency to be 2.5 cases
every 10,000,000 persons [96]. For calculative purposes, an annual figure of 100 HHA for the US
population seems a reasonable upper end estimate of the order of magnitude.
Established etiologic factors for HHA are thorium dioxide in angiography [97], exposure to vinyl
chloride monomer at the work place [98], and ingested inorganic arsenic [99]. Anabolic-androgenic
steroids have been associated, too [100]. No evidence of a relationship between environmental exposure
to vinyl chloride monomer and angiosarcoma of the liver has been built [93]. An association with low
dose, long-term PA exposure is without any epidemiological evidence [91]. The risk to experience
HHA due to PA contaminated biologicals is negligible. If it does exist, it must be minimal compared to
other largely accepted risks of daily living.
The overall comparison of experimental evidence, case reports and epidemiological evidence
highlights that qualitative acute and subacute toxicity data correspond. High PA doses lead to
a comparable specific liver pathology across species. However, regarding long term, low dose
exposure no link has been found between the liver carcinogenicity seen in rat animal models and the
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human situation. Since liver hemangiosarcomas are signal tumors for human carcinogens, the missing
accordance between rats and humans in PA tumorigenesis does not support the hypothesis that low
dose PA contamination of food implies a considerable human cancer risk. In contrast, a solid data base
exists demonstrating health protecting effects of T&HI.
While the PA-tumor link is unproven in humans, there exists a solid and consistent data base for
the health-protecting effects of T&HI.
5. PA Exposure in Humans: Main Sources, Ways to Avoid It, and Competitive Risks
5.1. Main Sources of Human PA Exposure
In 2015, an EFSA supporting publication assessed the occurrence of PA in animal and plant derived
products, teas, herbal infusions, and food supplements across different regions in Europe [5]. A total
of 1105 samples (746 of animal origin and 359 of plant origin) were covered. Animal derived samples
were mostly free of PA, which could partly be due to limits of the analytical method showing variable
recoveries and matrix interferences with meat. Milk showed occasionally (in 6% of 182 samples) low
levels of individual single PA. The analysis of the (herbal) tea samples revealed that a high proportion
(91% of 166 samples) contained one or more PA. Rooibos tea showed the highest concentration of the
sum of PA (mean concentration 7.99 µg/L) and chamomile tea the lowest (3.67 µg/L). Analyses of tea
sampled in the retail market have shown contaminations with PA in black, green, rooibos, melissa,
peppermint, chamomile, fennel, nettle, and mixed herbal tea [101].
In a recent systematic review of controlled trials, a liver related safety assessment of the intake of
green tea extracts concluded that adverse events associated with the liver are expected to be rare [102].
In 2016, EFSA published a dietary exposure assessment to PA in the European population via the
consumption of plant-derived food [103]. T&HI were by far the main contributors to total PA exposure.
Using a most recent data set submitted by THIE, the European association representing the producers
and traders of tea and herbal infusions, the estimated PA exposure was lower in comparison with
the original data set. This downward trend could be the result of manufactures to better control PA
contamination [103]. In conclusion, the habit of drinking (herbal) teas should be regarded as the major
source of human PA exposure.
In the same investigation, very high PA levels were reported for certain food supplements derived
from plant material of herbals known to synthesize PA. The authors underline the need to better
understand the sources and routes of plant derived PA contamination which are still largely unknown
but necessary to effectively reduce the contamination levels and the exposure of consumers [103].
Another well-known source of PA in dietary supplements are herbal plants used in traditional Chinese
medicine [64].
5.2. PA Contamination and Ways to Avoid and Control It
In general, herbs known to produce PA should be banned from food and beverages. Educated
herbalists know the plants they want to collect. The quality of certified wild collection of herbal plant
material depends on the education of herbal picking, i.e., identification of the right plants and using
the right techniques and times for harvesting. PA producing weeds are a specific challenge in large
scale industrial farming and production of herbal products and teas.
Guidelines to achieve good agricultural and collecting practice by adequate quality assurance
systems have been developed, e.g., by WHO [104] and EMA [47]. Especially if agricultural machines
are used for weeding and harvesting, it is most important to avoid adulteration with weed.
Stale seed bed is a useful weed control technique but involves personal inspections of cultivated
land area prior to seeding, during growth of herbs and before harvesting. To identify and destroy PA
synthesizing plants is labor-intensive and jeopardizes the cost of goods.
The use of herbicides in agriculture for weed control is associated with environmental risks
and against the expectations of most consumers of herbal infusions and teas. However, selective
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herbicides provide an efficient method of in-crop weed control and the agricultural industry takes
broad advantage of this opportunity [105].
Field robots in precision agriculture have been prototyped and shown to be able to establish
weed control by sensor technology, algorithms, and pattern recognition allowing to identify weed and
get rid of it mechanically [106]. Based on this technology, it could become possible to improve weed
control early in the value chain. Many raw herbal materials for the manufacturing of teas, infusions,
and supplements are still wild-crafted either due to impracticality or low commercial demand to
cultivate the species. In these cases, education is the key to avoid contamination of the harvest with PA
containing plants. While zero tolerance towards PA in foodstuff and herbal products is not an option,
minimization of human exposure is an option. In this respect, it is important to be informed about
everyday risks in general and about health risks associated and not associated with PA.
5.3. The Need to Consider Competitive Risks
There are different approaches to deal with competitive risks: One way is to compare the impact
of different modifiable risk factors on the manifestation of the disease under consideration.
Without doubt hepatitis B and C are the main causes for primary liver cancer. Consequently,
public health authorities focus on these risks [107,108].
Another way to look at competitive risk is to analyze the impact of tradeoffs. With focus on PA
contamination in foodstuff, one way to escape tea associated PA contamination would be avoiding tea
consumption and turn to alternative beverages, such as soft drinks.
An impressing example for the need to analyze competitive risks can be drawn from the data
of the (EPIC)-Norfolk study aimed to evaluate the association of different types of sugar-sweetened
beverages (SSB) with incident type 2 diabetes and determine the effects of substituting non-SSB for
SSB and the population-attributable fraction of type 2 diabetes due to total sweet beverages [109].
In adjusted Cox regression analyses, positive associations were shown for soft drinks, sweetened
milk beverages and artificially sweetened beverages but not for sweetened tea or coffee or fruit juice.
The analyses showed that each 5% of higher intake of energy (as a proportion of total daily energy
intake) from total sweet beverages was associated with an 18% higher risk of diabetes. Substituting
one serving/day of water or unsweetened tea/coffee for soft drinks and for sweetened-milk beverages
reduced the incidence of diabetes by 14–25%. The authors concluded if sweet beverage consumers
reduced intake to below 2% energy, 15% incident diabetes might be prevented. If avoidance of tea or
herbal infusions would lead to an increased consumption of non-alcoholic beverages with a higher
caloric burden, an increase in type 2 diabetes must be expected. The Center for Disease Control and
Prevention estimated for the U.S. population the number of Americans with type 2 diabetes in 2012 to
be 27.85 million cases (including 7.75 million undiagnosed). Thus, a rise of 18% translates to about
5 million (including 1.4 million undiagnosed) additional cases [110].
6. Balanced Risk–Benefit and Risk Communication
6.1. Objective versus Subjective Risks
Risk can be described as the product of the probability of occurrence and the amount of damage.
The concept of risk is a result of the great concerns in modern societies about the dangers of life. Public
health concerns often reflect perceptions following the media coverage of unfortunate events such as
foreign substances in food, outbreaks of mad cow disease, avian influenza, and the political decision
process on glyphosate [111]. Recent examples of pyrrolizidine alkaloids in honey and other foodstuffs
add to this picture. These circumstances lead to public distrust and uncertainties about food safety.
The diversity of conflicting opinions and special interests characterizes most public discussions about
health issues involving production and use of nature-derived products.
There is a hierarchy in source quality. Pseudo-facts can easily masquerade facts. It is necessary
to distinguish between claims with different levels of evidence. The more assumptions are needed
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to translate (e.g., analytical and experimental) data to the real human situation, the less evidence for
plausibility exists.
Management of public safety and health is a tool to overcome the gap between expert views
and public perception. The only thing that matters in effective risk assessment and applying risk
controls is to prevent morbidity and mortality in humans. To invest limited resources cost-effectively,
it is necessary to prioritize possible interventions. Risk assessment must provide state-of-the-art
information about specific quantified health risks and help to prioritize relative health risks for
decision makers.
Life is full of unforeseeable factors, and individual risks have only very limited predictability
for individual outcome. Risk comparison, however, is helpful to make decisions now based on
a prediction of the future, which by nature is uncertain. The level of effectiveness in reaching a desired
outcome (as an example, escape a liver tumor by change of personal lifestyle) is a continuum from
highly effective to ineffective or harmful. Risk comparison can frame the available information in an
information environment, which seems familiar or, at least, facilitates a better understanding [112–114].
Table 2 provides a risk ladder based on the most recent death statistics in Germany [115],
its taxonomy follows ICD 10 [116]. We use this data base to have a common source for the risk
comparison. All causes of death represent the disease without death due to secondary diseases,
e.g., death due to viral hepatitis ignores death through secondary diseases as liver cirrhosis and
primary liver cancers. Obviously, liver diseases should be a major German health concern, leading
to 4 times more annual deaths than car accidents. Hemangiosarcomas in general and HHA are not
recorded in the annual death statistic of Germany. One more lesson that can be learned from the risk
ladder is that two of the most prominent causes of death that are rarely dealt with in public discourse
are household accidents (10,000 deaths per million) and age (11,000 per million in the age range 60–65).
Table 2. Risk ladder.
Causes of Death Related to 1,000,000 Fatalities in Germany [108]
Cardiovascular disease 385,000
Cancer 250,000
Diabetes mellitus 26,000
Liver diseases 16,000
Age between 60 and 65 11,000
Household accidents 10,000
Liver cancer 8500
Car accidents 3800
Obesity 2200
Poisoning through pharmaceutical drugs 2000
Liver cancer (unexplained cause) 1700
Viral hepatitis 1000
Accidental poisoning 750
Unknown cause of death 270
Chronic hepatitis 20
PA-related death * ?
* PA-related risks or deaths not listed.
If PA contaminants ingested in low doses over a long time pose a human cancer risk, it is plausible
to analyze hepatic malignancies, because the liver is the most likely target organ [8]. No epidemiological
data exist to show a causal relationship between PA uptake and human cancer. However, absence
of evidence is not evidence of absence [117]. Although we cannot see any human tumor due to
PA ingestion, this does not prove from a formal point of view that PA do not cause malignancies
in humans.
To frame the potential risk, we can look at the different types of primary liver tumors, ask what
order of magnitude seems to be explained by established risk factors. We then take the remaining
tumors of unknown etiology as basis for an estimate of a risk which partly could be related to PA.
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To put this number into perspective we compare it to other morbidity or mortality risks. The possible
PA contamination of products of daily use can only play a negligible role in human liver deaths.
If we assume that HHA, the corresponding signal tumor to rodent liver angiosarcomas, is linked
to the intake of ubiquitously existing PA, it is obvious that such an event would be extremely rare,
practically undetectable, and extremely small compared to other largely accepted risks of daily living.
The available evidence suggests that drinking tea is a healthy custom resulting in improved
health conditions.
Based on our balanced risk–benefit analysis, abstinence from the consumption of T&HI is rated
counterproductive since the positive effects of tea will be missed and alternative beverages may well
be more hazardous, for example, sugar-sweetened soft drinks and alcoholic beverages. Nevertheless,
one could argue that quitting tea consumption is an easy way of avoiding the hypothetical risk of PA
intoxication. For a full picture of information, it is then useful to have a look at Figure 1. The icon
arrays, based on ideas of the Harding Center for Risk Communication (Berlin, Germany), allow for
comparing possible risks with benefits of drinking tea in selected health problems of 1000 persons
under observation [118]. Health effects of tea consumption are particularly pronounced in the case of
cardiovascular death. In a cohort study involving patients who experienced a myocardial infarction,
127 out of 1000 patients who consumed low amounts of tea died due to a cardiovascular event in the
observation. In the group of tea consumers only 98 out of 1000 died. Thus, 29 out of 1000 patients
profited from drinking tea. Comparable benefits could be derived from case-control studies involving
patients with ovarian cancer, breast cancer, and prostate cancer. In contrast, PA-related health
risks/benefits could not be quantified because of the lack of clinical or epidemiological data. These
examples highlight the necessity to adopt a broad perspective when weighing risks and benefits. In the
case of tea, avoiding a (hypothetical) risk may have the unexpected and unwanted consequence of
rejecting a convincing health benefit.
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6.2. PA Fact Collection to Provide Reference Points for Personal Decision Making
The present paper explores PA, tea consumption, and risk communication. The goal is to provide
easy to understand information and thus empower the readers to balance their PA-related risk and the
benefits of drinking T&HI to achieve an informed personal decision. Facts are compiled in four areas:
occurrence of PA, biological activity (toxicity) of PA, PA risks and risk prevention, and the benefits of
drinking teas.
Occurrence: PA are a group of chemically related products that are synthesized by many plants
and occur in the human environment as contaminants. Modern analytical methods allow detecting
even traces of PA in the human environment. The number of individually detectable PA is steadily
increasing. PA have been detected recently in more and more foodstuff, including green, black, and
herbal teas, honey, milk, lettuce, green vegetables as well as in herbal medicinal products and dietary
supplements. No evidence exists for an increase in the overall human burden from PA during the
last decades.
Biological activity and toxicity: PA become toxic after metabolic activation only, if doses exceed
the detoxification capacity of the exposed organism. Conventional experimental toxicology studies
show toxic effects with a specific form of hepatic veno-occlusive disease. In standardized tests,
mutagenic, genotoxic, and tumor inducing properties, specifically hemangiosarcomas of the liver,
have been described. Poisoning in ruminants by PA producing plants lead to damages comparable to
findings observed in toxicity testing. Subacute liver toxicity, including hepatic veno-occlusive disease,
was described repeatedly in people living in remote rural areas after contaminated flour was used in
the bakery. Contamination resulted from adulteration with PA producing weeds. Acute poisoning in
humans leading to toxic symptoms without delay is accidental and extremely rare. Single episodes
have been reported after accidental consumption of food made from PA synthesizing plants.
PA risks and risk prevention: PA has attracted attention recently due to better analytical methods.
For T&HI, a strong safety record in both healthy individuals and clinical populations is established.
However, it is unknown if a human risk results from incorporating low doses of PAs on a regular basis.
If this risk exists, no quantification of its health impact has been established. Prevention or reduction
of human PA exposure aims to avoid possible harms resulting from long-term, low dose toxic burden.
No tolerable human threshold doses for individual or the sum of PA have been established from real
world evidence, and current recommended regulatory threshold values are based on experimental
data only.
Quantitative extrapolation from PA animal data to humans must accept big knowledge gaps
resulting in big uncertainties. To bridge these uncertainties, broad safety factors are applied to establish
limit values which possess a reasonable certainty of doing no harm (Margin of exposure animal:
human > 10,000). It is unknown if a general human risk through PA exists. T&HI are just one source
of possible PA contamination through foodstuff, and this risk can only be partly responsible for the
overall human risk due to PA. If a human risk for chronic toxicity of PA exists, it must be small in
comparison to other, frequently accepted risks of human daily living. One way of reducing the risk
of consuming PA is avoiding the consumption of T&HI. This would come at the expense of missing
the positive and well-proven positive health effects of T&HI. There is no evidence that a healthier
alternative exists by replacing the habit of drinking T&HI by switching to other beverages. There is
significant evidence that replacing tea drinking by other beverages (e.g., high caloric soft drinks) could
result in poorer health.
It is possible that higher PA risks exist for selected small groups under special circumstances,
e.g., by transplacental exposure during pregnancy or in populations with underlying liver diseases
resulting in compromised detoxification capacities.
Benefits of drinking teas: T&HI are worldwide consumed as tasty, healthy, and low-caloric
beverages. Heating water before drinking reduces infectious risks, thus, in remote areas, drinking
tea can prevent infections. Experimental studies, clinical studies and epidemiological data link tea
consumption to beneficial health effects, including risk reduction for several types of cancer, type 2
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diabetes, and cardiovascular diseases. Herbal teas are approved as herbal medicinal products by
regulatory authorities. A positive risk–benefit ratio is mandatory for market access for all medicinal
products. The evidence showing beneficial effects of T&HI is progressively increasing. However,
no final scientific consensus exists on the extent of the health benefits resulting from daily drinking
different types of T&HI. Despite the lack of convincing evidence from long-term intervention studies
an increase in consumption of tea, with a negligible calorie load is encouraged.
7. Conclusions
Based on the current scientific data, drinking teas and herbal infusions is considered a recommendable
habit associated with multiple health benefits.
At the same time, manufacturers must continue their efforts to secure good product quality,
to keep PA contamination as low as possible and to be transparent on their measures of quality control
and risk communication.
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